CAMBRIDGE, Mass.– C4 Therapeutics (C4T) today announced the appointment of Michael Kim, Ph.D., as Vice President of Business Development. Dr. Kim comes to C4 Therapeutics from ARIAD Pharmaceuticals where he held responsibilities for partnering activities around early and late stage programs in addition to portfolio strategy and alliance management.
He started his business career as a strategy consultant with Leerink Swann and Company and progressed to Corporate Strategy and Business Development roles of increasing responsibility at Alkermes, Vertex Pharmaceuticals and FORUM Pharmaceuticals. He received his post-doctoral training as an NIH NRSA Fellow at Harvard Medical School and holds a Ph.D. in Biomedical Engineering from the University of Rochester.
“We are incredibly pleased to have Michael join us,” said Andy Phillips, C4T’s President and Chief Scientific Officer. “Michael’s combined scientific and business background, coupled to his track record in matching portfolio strategy with external opportunities, are a superb match for C4T. We are all looking forward to the impact he will bring during this next exciting phase of C4T’s growth.”
About C4 Therapeutics
C4 Therapeutics is pioneering a new class of drugs. C4’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.